Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers

被引:24
|
作者
Ochoa, Dolores [1 ]
Prieto-Perez, Rocio [1 ]
Roman, Manuel [1 ]
Talegon, Maria [1 ]
Rivas, Angela [1 ]
Galicia, Ignacio [2 ]
Abad-Santos, Francisco [1 ,3 ]
Cabaleiro, Teresa [1 ,3 ]
机构
[1] Hosp Univ Princesa, Clin Pharmacol Serv, Inst Teofilo Hernando, Inst Invest Sanitaria Princesa IP, Madrid 28006, Spain
[2] Fdn Teofilo Hernando, Madrid 28049, Spain
[3] Inst Salud Carlos III, CIBERehd, Madrid 28029, Spain
关键词
CYP2C8; CYP2C9; ibuprofen; pharmacokinetics; polymorphisms; CYTOCHROME P4502C9 POLYMORPHISMS; IN-VITRO; FUNCTIONAL-CHARACTERIZATION; HEALTHY-VOLUNTEERS; METABOLISM; PHARMACODYNAMICS; GENOTYPES; ACID; (R)-IBUPROFEN; VARIABILITY;
D O I
10.2217/pgs.15.40
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: To evaluate the effect of polymorphisms in CYP2C9 and CYP2C8 and gender on the pharmacokinetics of the enantiomeric forms of ibuprofen. Materials & methods: 122 healthy volunteers were genotyped for polymorphisms in CY2C8 and CYP2C9 using real-time PCR. Results:CYP2C8 polymorphisms affected neither R- nor S-ibuprofen. CYP2C9*3 and CYP2C9*2 carriers had a lower S-ibuprofen clearance and a higher S-ibuprofen AUC and half-life. R-ibuprofen clearance was decreased in CYP2C9*3 carriers. Gender affected R-ibuprofen and S-ibuprofen pharmacokinetics. Multiple regression analysis showed that CYP2C9*2, CYP2C9*3 and gender were associated with S-ibuprofen clearance, but only CYP2C9*3 was associated with R-ibuprofen clearance. Conclusion: The pharmacokinetics of S-ibuprofen and R-ibuprofen is affected by CYP2C9 polymorphisms and gender. CYP2C8 polymorphisms do not have a significant role. Original submitted 6 February 2015; Revision submitted 1 April 2015
引用
收藏
页码:939 / 948
页数:10
相关论文
共 50 条
  • [41] Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast
    Hyun-Jee Lee
    Young-Hoon Kim
    Se-Hyung Kim
    Choong-Min Lee
    Ae-Yun Yang
    Choon-Gon Jang
    Seok-Yong Lee
    Jung-Woo Bae
    Chang-Ik Choi
    Archives of Pharmacal Research, 2016, 39 : 1013 - 1019
  • [42] Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast
    Lee, Hyun-Jee
    Kim, Young-Hoon
    Kim, Se-Hyung
    Lee, Choong-Min
    Yang, Ae-Yun
    Jang, Choon-Gon
    Lee, Seok-Yong
    Bae, Jung-Woo
    Choi, Chang-Ik
    ARCHIVES OF PHARMACAL RESEARCH, 2016, 39 (07) : 1013 - 1019
  • [43] Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics
    Kirchheiner, J
    Müller, G
    Meineke, I
    Wernecke, KD
    Roots, I
    Brockmöller, J
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (05) : 459 - 466
  • [44] Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine
    Green, Bruce
    Crauwels, Herta
    Kakuda, Thomas N.
    Vanveggel, Simon
    Brochot, Anne
    CLINICAL PHARMACOKINETICS, 2017, 56 (05) : 525 - 536
  • [45] Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine
    Bruce Green
    Herta Crauwels
    Thomas N. Kakuda
    Simon Vanveggel
    Anne Brochot
    Clinical Pharmacokinetics, 2017, 56 : 525 - 536
  • [46] Functional impact of CYP2C*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans
    Allabi, AC
    Gala, JL
    Horsmans, Y
    Babaoglu, MO
    Bozkurt, A
    Heusterspreute, M
    Yasar, U
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (02) : 113 - 118
  • [47] Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic DrugsClinical Relevance
    Julia Kirchheiner
    Ivar Roots
    Mark Goldammer
    Bernd Rosenkranz
    Jürgen Brockmöller
    Clinical Pharmacokinetics, 2005, 44 : 1209 - 1225
  • [48] Distribution of polymorphisms in the CYP2C9 gene and CYP2C19/CYP2C9 haplotypes among Venezuelan populations
    Flores-Gutierrez, Sara
    Rodriguez-Larralde, Alvaro
    Vivenes de Lugo, Merlyn
    Castro de Guerra, Dinorah
    ANNALS OF HUMAN BIOLOGY, 2017, 44 (02) : 191 - 198
  • [49] Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP
    Tan, Ming-Liang
    Yoshida, Kenta
    Zhao, Ping
    Zhang, Lei
    Nolin, Thomas D.
    Piquette-Miller, Micheline
    Galetin, Aleksandra
    Huang, Shiew-Mei
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (05) : 854 - 867
  • [50] Effect of CYP2C8 genotype on rosiglitazone pharmacokinetics.
    Hruska, MW
    Cheong, JA
    Amico, JA
    Langaee, TY
    Frye, RF
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P36 - P36